Zhang Qinghao, Liu Qi, Wu Jingjing, Wang Changyuan, Peng Jinyong, Ma Xiaochi, Liu Kexin
Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian 116044, China.
Eur J Pharmacol. 2009 Jun 10;612(1-3):9-14. doi: 10.1016/j.ejphar.2009.03.081. Epub 2009 Apr 14.
Cefditoren is a third-generation cephalosporin developed by Meiji Seika Kaisha Ltd. Many beta-lactam antibiotics are transported by the H+/peptide symporters PEPT1 and PEPT2 that are preferentially expressed in the luminal membrane of the intestine and kidney, respectively. In this study, we employed everted small intestinal preparations, in situ jejunal perfusion, and Caco-2 cells as models to determine the effects of glycylsarcosine (Gly-Sar) and clonidine on uptake and transport of cefditoren. In vivo, rats were administered cefditoren (10 mg/kg) intravenously, in the absence and presence of Gly-Sar (10 mg/kg). The effects of Gly-Sar coadministration on biliary and urinary cefditoren excretion were investigated. Gly-sar significantly decreased cefditoren uptake and transport in the three in vitro and in situ models. A kinetic study showed that cefditoren transport by PEPT1 in Caco-2 cells had K(m) and V(max) values of 0.94+/-0.11 mM and 0.49+/-0.09 nmol/mg protein/5 min, respectively. Clonidine induced a 50% increase of cefditoren absorption across the intestinal mucosa after intravenous infusion, in the jejunal perfusion model. In vivo, biliary and urinary excretions over 6 h were an average of 34% and 4% of the administered cefditoren respectively. Gly-Sar coadministration increased the renal clearance of cefditoren by 200% and values of CL(urine) for cefditoren in the presence of 50 mM Gly-Sar were significantly higher than the controls. Biliary excretion was unchanged, however, compared to cefditoren alone. This study provides the first in vitro and in vivo evidence that cefditoren is a substrate of PEPT1.
头孢妥仑是由明治制果株式会社研发的第三代头孢菌素。许多β-内酰胺类抗生素是由H⁺/肽同向转运体PEPT1和PEPT2转运的,它们分别优先表达于小肠和肾脏的管腔膜。在本研究中,我们采用外翻小肠制剂、原位空肠灌注和Caco-2细胞作为模型,以确定甘氨酰肌氨酸(Gly-Sar)和可乐定对头孢妥仑摄取和转运的影响。在体内,给大鼠静脉注射头孢妥仑(10mg/kg),同时给予或不给予Gly-Sar(10mg/kg)。研究了Gly-Sar共同给药对头孢妥仑胆汁和尿液排泄的影响。Gly-Sar在三种体外和原位模型中均显著降低了头孢妥仑的摄取和转运。动力学研究表明,Caco-2细胞中PEPT1介导的头孢妥仑转运的K(m)和V(max)值分别为0.94±0.11mM和0.49±0.09nmol/mg蛋白/5min。在空肠灌注模型中,静脉输注可乐定后,头孢妥仑经肠黏膜的吸收增加了50%。在体内,6小时内胆汁和尿液排泄量分别平均为给药量的34%和4%。Gly-Sar共同给药使头孢妥仑的肾清除率提高了200%,在50mM Gly-Sar存在下头孢妥仑的CL(尿液)值显著高于对照组。然而,与单独使用头孢妥仑相比,胆汁排泄没有变化。本研究提供了首个体外和体内证据,证明头孢妥仑是PEPT1的底物。